Pharmacology and Biotechnology in Medical Practice

Daten

Offizielle Daten in der Fachveröffentlichung für das folgende akademische Jahr: 2022-2023

Thematik

The aims of the course are: showing the history of the drug research and modes of the drug development, presenting information about the phases of rational drug design, from the plan of the molecules to clinical trials.The aim of the course is to provide an overview of drug development and introduce its methodology. The students will hear about rational drug design, starting from molecular design to clinical tirals. General pharmacology: Farmakokinetics, absorption, repartition, biotransformation, excretion. Farmakodinamics, drug binding targets, receptors, efficacy studies. Detection of the effects at various levels (molecular, cell, organ, organism). Dose dependency. Drug selectivity and safety. Tolerance. Drug interactions. Products suitable for gene therapy and their pharmacological characteristics. Immune pharmacology: target molecules of biotechnological products that influence the immune system. Monoclonalis antitestek, citokinek farmakoterápiás hatásai, mellékhatásai. Unexpected inflammation and allergic reactions. Citokine release syndrome. Oncopharmacology: Monoclonal antibodies, colony stimulating factors, interleukins in pharmacotherapy, side-effects. Fermentation of Antibiotics, antifungals, antivirals and their pharmacology. Pharmacotherapy of endokrin diseases using recombinant hormones and peptides. Optimization of results. Pharmacological products prepared from human blood. Production and quality control of cellular products suitable for human therapy.

Vorlesungen

• 1. History of drugs - Dr. Sánticsné Dr. Pintér Erika
• 2. History of drugs - Dr. Sánticsné Dr. Pintér Erika
• 3. Strategies of drug development - Dr. Bölcskei Kata
• 4. Strategies of drug development - Dr. Bölcskei Kata
• 5. Target validation - Dr. Szőke Éva
• 6. Target validation - Dr. Szőke Éva
• 7. High throughput screening - Dr. Szőke Éva
• 8. High throughput screening - Dr. Szőke Éva
• 9. Preclinical testing - Dr. Bölcskei Kata
• 10. Preclinical testing - Dr. Bölcskei Kata
• 11. Preclinical testing - Dr. Pozsgai Gábor
• 12. Preclinical testing - Dr. Pozsgai Gábor
• 13. Mechanisms of drug actions - Dr. Csekő Kata
• 14. Mechanisms of drug actions - Dr. Csekő Kata
• 15. Quantitative pharmadynamics - Dr. Csekő Kata
• 16. Quantitative pharmadynamics - Dr. Csekő Kata
• 17. Pharmacokinetic aspects of drug development - Dr. Pethő Gábor István
• 18. Pharmacokinetic aspects of drug development - Dr. Pethő Gábor István
• 19. Pharmacokinetic aspects of drug development - Dr. Pethő Gábor István
• 20. Pharmacokinetic aspects of drug development - Dr. Pethő Gábor István
• 21. Toxicity testing - Dr. Gregus Zoltán
• 22. Toxicity testing - Dr. Gregus Zoltán
• 23. Human phase studies - Dr. Bölcskei Kata
• 24. Human phase studies - Dr. Bölcskei Kata
• 25. Human phase studies - Dr. Bölcskei Kata
• 26. Human phase studies - Dr. Bölcskei Kata
• 27. GMP, GLP, GCP - Dr. Bölcskei Kata
• 28. GMP, GLP, GCP - Dr. Bölcskei Kata

Praktika

Seminare

Materialien zum Aneignen des Lehrstoffes

Obligatorische Literatur

Vom Institut veröffentlichter Lehrstoff

Skript

Empfohlene Literatur

1. Povl Krogsgaard-Larsen, Tommy Liljefors, Ulf Madsen: Textbook of Drug Design and Discovery, 3rd edition, New York, Oxford University Press
2. Edward Harvel Kerns, Li Di: Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization, Academic Press, 2008
3. Ronald P. Evens: Drug and Biological Development: From Molecule to Product and Beyond, Springer, 2007
4. Rick Ng: Drugs: From Discovery to Approval, 2nd edition, Wiley-Blackwell, 2008
5. Bert Spilker: Guide to Drug Development: A Comprehensive Review and Assessment, Kluwer, 2008
6.Textbook of Drug Design and Discovery, Third Edition by Povl Krogsgaard-Larsen, Tommy Liljefors, Ulf Madsen, New York, Oxford University Press, 2. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization by Edward Harvel Kerns, Li Di, Academic Press, 2008; 3. Drug and Biological Development: From Molecule to Product and Beyond by Ronald P. Evens, Springer, 2007; 4. Drugs: Fro

Voraussetzung zum Absolvieren des Semesters

Maximum of 15 % absence allowed

Semesteranforderungen

none

Möglichkeiten zur Nachholung der Fehlzeiten

none

Prüfungsfragen

written test

Prüfer

• Dr. Szőke Éva

Praktika, Seminarleiter/innen

• Dr. Bölcskei Kata
• Dr. Csekő Kata
• Dr. Gregus Zoltán
• Dr. Pethő Gábor István
• Dr. Pozsgai Gábor
• Dr. Sánticsné Dr. Pintér Erika
• Dr. Szőke Éva